United States Neurodegenerative Disease Therapeutics Market 2025: Industry Developments, Future Growth, Share & Industry Insights | AbbVie Inc, Amneal Pharmaceuticals LLC, Eisai Co Ltd, Merck KGaA, Novartis AG

Neurodegenerative Disease Therapeutics Market size reached US$ 12.52 Billion in 2024 and is expected to reach US$ 28.78 Billion by 2033, growing at a CAGR of 9.8% during the forecast period 2025-2033.

According to DataM Intelligence Comprehensive Report has released its latest report on the "Neurodegenerative Disease Therapeutics Market Size 2025," providing a detailed analysis of market trends, key growth drivers, competitive landscape, and regional insights. The report includes market size (value and volume), CAGR projections, and emerging opportunities that help businesses identify growth areas and build effective strategies. Backed by data-driven insights and future outlook, this study serves as a valuable resource for companies looking to stay competitive and capitalize on market potential.

Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/neurodegenerative-disease-therapeutics-market?sg

Industry Latest News 2025:

✅ 2025-01-09 (USA): Johnson & Johnson exercised its option / completed an asset purchase of Arkuda Therapeutics' lysosomal-function enhancer portfolio (upfront payment with milestones).

✅ 2025-01-13 → 2025-04-02 (USA): Johnson & Johnson announced and then closed its acquisition of Intra-Cellular Therapies (≈$14.6B) to bolster its neuroscience/CNS pipeline.

✅ 2025-05-21 (USA): Sanofi agreed to acquire Vigil Neuroscience for $470M to strengthen its Alzheimer's/neurology pipeline (VG-3927 oral program in development).

✅ 2025-06-16 (USA): Supernus Pharmaceuticals announced acquisition of Sage Therapeutics (up to $795M), giving Supernus access to Sage's CNS assets including Zurzuvae and neurological programs.

✅ 2025-03-25 (Japan): Eisai highlighted/recognized LEQEMBI® (lecanemab) as a world-first early-Alzheimer's treatment in Japan (company announcement/award around Mar 25, 2025).

✅ 2025-04-16 (Europe - EMA): European Commission / regulatory materials: lecanemab (LEQEMBI) authorized in EU for early Alzheimer's (EMA/press materials dated April 2025).

✅ 2025-08-25 (Europe): Eisai/Biogen began EU commercial launches of Leqembi in Austria (Aug 25, 2025) with Germany following - controlled-access rollout announced.

✅ 2025-04-07 (Korea): ABL Bio (Seongnam, Korea) entered a multi-program collaboration with GSK to develop neurodegenerative disease programs using ABL's BBB delivery platform (announcement Apr 7, 2025).

✅ 2025-07-16 (Korea): Seoul-based Illimis Therapeutics raised a $42M (≈58 billion won) financing round to advance Alzheimer's-focused programs (Korean biotech fundraising / R&D expansion).

Market Geographical Share:

North America dominates the global neurodegenerative disease therapeutics market due to strong healthcare infrastructure, high R&D spending, and the presence of leading pharmaceutical innovators. The U.S. accounts for the largest share, driven by active clinical research and favorable regulatory approvals.

Europe holds a substantial market share owing to increasing patient awareness, government support for neurological research, and the expansion of precision medicine programs. Countries like Germany, the U.K., and France are key contributors.

The Asia-Pacific region is expected to register the fastest growth rate, fueled by a rapidly aging population, rising healthcare investments, and expanding access to advanced therapies in Japan, China, and South Korea.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/neurodegenerative-disease-therapeutics-market?sg

Market Growth Drivers:

✅ Rising Disease Incidence:
The global population is aging rapidly, leading to a surge in neurodegenerative disorders. The growing elderly demographic particularly in developed regions is a key factor accelerating therapeutic demand.

✅ Advancements in Biomarker Research and Precision Medicine:
Progress in biomarker identification and genomics has enhanced early diagnosis and personalized treatment, improving the success rates of clinical trials and expanding the therapeutic pipeline.

✅ Innovation in Drug Development and Delivery:
Emerging platforms such as gene therapy, stem cell therapy, and monoclonal antibodies are transforming the treatment paradigm. Nanotechnology-based drug delivery systems are further improving drug efficacy and targeting.

✅ Government and Private Sector Initiatives:
Supportive funding from governments, healthcare agencies, and nonprofit organizations for neuroscience research is boosting R&D activities, fostering new drug approvals and clinical collaborations.

✅ Growing Awareness and Diagnosis Rates:
Increased public health campaigns and improved diagnostic tools have led to early detection and management of neurodegenerative diseases, thereby fueling therapeutic adoption.

Segments Covered in the Beverage Premix Market:

By Drug Class (Dopamine Agonists, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators, Others)

By Disease Type (Parkinson's Disease, Amyotrophic Lateral Sclerosis, Alzheimer's Disease, Huntington Disease, Others)

By Route of Administration (Oral, Injection, Transdermal)

Regional Analysis for Beverage Premix Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now & Get 30% OFF - Grab 50% OFF on 2+ reports: https://www.datamintelligence.com/buy-now-page?report=neurodegenerative-disease-therapeutics-market?sg

Major Key Players: AbbVie Inc, Amneal Pharmaceuticals LLC, Eisai Co Ltd, F. Hoffmann-La Roche Ltd, Merck KGaA, Novartis AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Otsuka Pharmaceutical Co Ltd and Orion Corporation.

✅ AbbVie Inc. - A major investor in neuroscience R&D with a broad pipeline (dozens of programs and substantial 2024 R&D spend), positioning AbbVie as a sizable contender for future neurodegenerative franchises rather than a current single-drug market leader.

✅ Amneal Pharmaceuticals LLC - Gained a clear commercial foothold in Parkinson's therapeutics after FDA approval of CREXONT (carbidopa/levodopa extended-release), giving Amneal an immediately addressable PD market opportunity and near-term revenue runway in movement disorders.

✅ Eisai Co., Ltd. - One of the most visible Alzheimer's players thanks to lecanemab (Leqembi): commercial sales have begun and regulatory outcomes have moved between rejection, re-examination, and approvals in major regions making Eisai both a revenue driver and a focal point for the market's regulatory risk/reward story.

✅ Hoffmann-La Roche Ltd (Roche) - Strong incumbent in neuroimmunology and multiple sclerosis (e.g., OCREVUS) with large, established sales in neuro-therapeutics and ongoing late-stage programmes Roche represents steady, high-value market share within neurodegenerative/neurology segments.

✅ Merck KGaA - Maintains a strategic neuroscience research focus (neurology and immunology crossovers) and a pipeline aimed at disease modification; Merck KGaA is therefore a medium-to-large strategic player whose exact market share varies by indication but contributes meaningfully to neuroscience R&D intensity.

✅ Novartis AG - Actively expanding its neurodegenerative footprint via licensing and M&A deals (recent large Parkinson's licensing activity) and broad neuroscience programmes reported in its annual disclosures Novartis combines sizeable balance-sheet resources with targeted dealmaking to grow market share.

Unlimited Insights. One Subscription: https://www.datamintelligence.com/reports-subscription?sg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.